Lung cancer remains the deadliest malignancy on the planet, and a sweeping new analysis of twenty years of scientific publishing shows exactly where the global research community has placed its bets in the fight against it. In a bibliometric study published in Clinical Cancer Bulletin, researchers led by Mengyao Sun and Zejun Jia of Zhongshan Hospital, Fudan University, mined the Web of Science Core Collection for publications spanning 2005 to 2024 that describe small molecule compounds active against lung cancer. Using the network-mapping tools VOSviewer and CiteSpace, the team charted publication trends, collaboration networks, patent activity and keyword evolution across 4,870 articles. The result is one of the most detailed cartographic portraits to date of a research field that has quietly delivered dozens of approved drugs while struggling to convert laboratory promise into bedside benefit.
The scale of the field is striking. Since 2011, annual publication output has climbed steadily, driven overwhelmingly by Asia. China dominates raw productivity: of the ten most prolific institutions in the field, eight are Chinese, with the Chinese Academy of Sciences leading at 215 publications, followed by Sichuan University with 164 and Zhejiang University with 146. In total, 91 countries and 5,052 institutions contributed to the literature, and 5,973 authors appear in the dataset. Yet productivity and influence tell different stories. The United States, while trailing in output, leads decisively in citation impact, averaging 52.79 citations per publication and holding the highest centrality in the collaboration network, a measure of how often it acts as the connective tissue between research clusters. Four of the ten most published authors are affiliated with Chinese institutions, but the majority of the most frequently co-cited researchers, the scientists whose work others build upon, are American.
Why do small molecules matter so much in lung cancer? These are organic compounds, typically weighing less than 1,000 daltons, with hydrophobic properties that let them slip across cell membranes and even the blood-brain barrier. That permeability is a decisive advantage over antibody therapies and cancer vaccines, because it allows the drugs to reach intracellular enzymes, kinases and mutant proteins, including those driving brain metastases, a common and feared complication of lung cancer. Their chemistry also permits rapid structural modification, which is precisely what clinicians need when tumors evolve resistance. Add oral bioavailability, which improves patient compliance, and cost-effective manufacturing, which improves access in resource-limited settings, and the case becomes clear: despite the rise of biologics and immunotherapy, small molecules remain first-line weapons in precision oncology.
The bibliometric data capture a field in transition. Before 2015, keyword bursts clustered around angiogenesis and in vivo and in vitro experimental methods, reflecting an era when the priority was proving that compounds could choke tumor blood supply and kill cancer cells in living systems. After 2016, the frontier shifted decisively toward molecular docking, migration and metabolism, signaling a move from blunt cytotoxicity toward computationally guided, mechanism-driven drug design. The most persistent keywords across two decades were drug resistance, inhibitor, apoptosis, metastasis and molecular docking, and the co-occurrence analysis organized the literature into five thematic clusters: apoptosis, gefitinib, molecular docking, invasion and non-small cell lung cancer. The most co-cited reference in the entire corpus is a 1983 methodological paper by T. Mosmann describing a colorimetric assay for cellular growth and survival, cited 196 times within the dataset, a reminder that the field still rests on decades-old laboratory techniques for validating anticancer activity.
The clinical arc of the field is best told through the epidermal growth factor receptor, or EGFR. The first-generation tyrosine kinase inhibitor gefitinib reversibly blocks EGFR phosphorylation and produced dramatic responses in patients with sensitizing mutations such as exon 19 deletion and exon 21 L858R, mutations that occur in 10 to 15 percent of Caucasian non-small cell lung cancer patients and 30 to 50 percent of East Asian patients. But resistance emerged rapidly, and the response illustrates the iterative logic of small molecule development. Second-generation inhibitors were engineered with side chains that covalently bind the cysteine 797 residue via Michael addition, irreversibly shutting down EGFR autophosphorylation. When sequencing technology revealed further resistance mutations, third-generation inhibitors were designed to target the mutant protein selectively, reducing resistance and side effects. To date, the analysis counts 48 small molecule drugs approved by the FDA or China’s NMPA for lung cancer, spanning EGFR, ALK, BRAF, ROS1 and KRAS inhibitors.
Resistance, however, remains the field’s central nemesis, and the study documents how researchers are chasing it down signaling cascades. MET gene amplification, which activates HER3/PI3K bypass signaling in EGFR-inhibitor-resistant tumors, has become a key target; the MET inhibitor savolitinib achieved a 49.2 percent objective response rate in clinical trials. Downstream mutations in BRAF, KRAS and PIK3CA have prompted combination strategies: the dabrafenib-trametinib pairing in BRAF V600E-mutant patients delivered a 63.9 percent response rate, 14.6 months of median progression-free survival and 24.6 months of median overall survival in a phase II trial. Epigenetic mechanisms are also in play, with preclinical evidence supporting DNA methyltransferase inhibitors such as EGCG and procainamide, and histone deacetylase inhibitors including ricolinostat and pracinostat, as candidates for combination therapy in non-small cell lung cancer.
Perhaps the most sobering number in the analysis is 3.8 percent. That is the proportion of the 4,870 studies that reached clinical trial stage, with 136 clinical trials identified, 111 in phase 2 and 75 in phase 3. By contrast, drug chemistry studies, work on molecular library construction, structure-activity relationship optimization and ADMET parameter refinement, account for 10.7 percent of output, and 520 studies focused on drug synthesis or validation of natural bioactive compounds. The field, in other words, is heavy on target validation and preclinical development and thin on translation. The authors attribute the bottleneck to low compound screening efficiency, prohibitive trial costs and protracted regulatory timelines. Their proposed remedies include a bedside-to-bench-to-bedside strategy to accelerate mechanistic understanding, phase 0 trials for early pharmacokinetic and pharmacodynamic assessment, and integration of generative artificial intelligence and organoid-on-chip platforms to improve clinical predictability.
Patent analysis adds a commercial dimension to the map. Among highly published and highly cited authors, patent portfolios concentrate overwhelmingly in drug synthesis technologies, and most active authors show substantial patent productivity. Intriguingly, the two South Korean investigators in the top ranks hold no registered patents, suggesting a research culture oriented toward mechanistic exploration rather than applied development, and highly cited authors do not consistently hold more patents than their less-cited peers. The journal landscape tells its own story: the most prolific outlets are the European Journal of Medicinal Chemistry with 159 publications, Oncotarget with 117 and Molecular Cancer Therapeutics with 105, while the most cited are Cancer Research with 2,896 citations, Clinical Cancer Research with 2,296 and Oncogene with 1,831. Notably, only 35 percent of the top 20 publishing journals overlap with the top 20 most-cited journals, which the authors read as a signal that output quality and academic influence have room to grow.
Looking forward, the study identifies several frontiers. Small cell lung cancer, about 15 percent of cases with a five-year survival below 10 percent, has been poorly served by targeted therapy because its recurrent mutations in TP53, RB1 and other genes are common across cancers; but germline mutations in DNA repair genes such as RAD51D, CHEK1, BRCA2 and MUTYH offer new angles, and inhibitors are in preclinical development. Metabolic targets are rising fast, from GUK1 phosphorylation in ALK-positive lung cancer to the enzymes UXS1 and GFAT1, while immune-focused targets such as CSF-1R, STING and the tryptophan-degrading enzyme IDO1 are in clinical evaluation. Natural products, with more than 3,000 phytochemicals cataloged with anti-lung-cancer activity, offer higher clinical trial success rates than synthetic drugs but suffer from poor solubility and metabolic instability. Drug repurposing, exemplified by the AKR1B10 inhibitor epalrestat overcoming chemotherapy resistance, and advanced delivery platforms, from liposomal irinotecan, which doubled response rates in the phase 3 RESILIENT trial, to antibody-drug conjugates and inhaled formulations, round out the pipeline. The authors’ conclusion is unambiguous: small molecules are not going anywhere, and the next decade will be decided by who can best combine artificial intelligence, smarter chemistry and better delivery to stay ahead of resistance.
Subject of Research: Bibliometric analysis of small molecule drug research in lung cancer targeted therapy from 2005 to 2024
Article Title: Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024)
Article References: Sun, M., Yin, Y., Chen, D., & Jia, Z. (2025). Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024). Clinical Cancer Bulletin, 4(1), Article 13. https://doi.org/10.1007/s44272-025-00041-3
Image Credits: AI Generated
DOI: 10.1007/s44272-025-00041-3
Keywords: lung cancer, small molecules, targeted therapy, bibliometric analysis, EGFR inhibitors, drug resistance, molecular docking, non-small cell lung cancer, drug discovery, combination therapy, drug repurposing, drug delivery systems
Cite Scienmag News
APA MLA Chicago
Louis Brooks. (October 1, 2026). Two Decades of Data Reveal How Small Molecule Drugs Reshaped Lung Cancer Treatment. Scienmag. https://scienmag.com/two-decades-of-data-reveal-how-small-molecule-drugs-reshaped-lung-cancer-treatment/
Louis Brooks. “Two Decades of Data Reveal How Small Molecule Drugs Reshaped Lung Cancer Treatment.” Scienmag, 1 October 2026, https://scienmag.com/two-decades-of-data-reveal-how-small-molecule-drugs-reshaped-lung-cancer-treatment/. Accessed 1 October 2026.
Louis Brooks. “Two Decades of Data Reveal How Small Molecule Drugs Reshaped Lung Cancer Treatment.” Scienmag. October 1, 2026. https://scienmag.com/two-decades-of-data-reveal-how-small-molecule-drugs-reshaped-lung-cancer-treatment/
Copy citation Download RIS
Tags: analysis of scientific publications on lung cancerBibliometric analysisbibliometric analysis of lung cancer treatmentsChinese contributions to lung cancer drug researchcombination therapydrug delivery systemsdrug discoverydrug repurposingdrug resistanceEGFR inhibitorsevolution of keywords in lung cancer drug researchglobal research trends in lung cancer drug developmentimpact of Asia on lung cancer treatment advancementslung cancerlung cancer small molecule drug researchmolecular dockingnetwork mapping of lung cancer research collaborationsnon-small cell lung cancerpatent activity in small molecule lung cancer drugsprogress in translating small molecule drugs to clinical usepublication trends in lung cancer targeted therapiessmall molecule compounds in lung cancer therapysmall moleculesTargeted therapy
